AZ's COVID-19 Antibody Combo Protects For Longer But Access Issues Persist
Positive Clinical Update On Evusheld
Executive Summary
AstraZeneca has presented more promising data from the PROVENT trial of its antibody combination therapy Evusheld which shows high levels of protection from COVID-19 for at least six months.
You may also be interested in...
AstraZeneca’s Farxiga Flies Across $1bn Barrier
First-quarter sales jumped by 56% to $11.39bn at AstraZeneca and while its COVID-19 products brought in $1.6bn, it was the performance of the diabetes, heart failure and chronic kidney disease drug Farxiga that impressed most.
AstraZeneca Focuses On COVID-19 Antibody Approach After Year Of Vaccine Headwinds
During its fourth quarter earnings call, the UK-based major expressed hopes that its prophylactic antibody approach would fare better after its COVID-19 jab faced several obstacles in developed markets last year.
PTC Confident About Commercial Prospects For Gene Therapy Upstaza
PTC CEO Stuart Peltz tells Scrip that cost watchdogs are likely to look favorably on the firm’s transformational gene therapy for a distressing rare brain disorder in children who could not even lift their heads before treatment.